Mylan (NASDAQ:MYL) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report issued on Tuesday.

Other research analysts also recently issued research reports about the company. Cowen reaffirmed a “hold” rating and issued a $31.00 price objective on shares of Mylan in a research note on Thursday, August 9th. Wells Fargo & Co reaffirmed a “hold” rating on shares of Mylan in a research note on Wednesday, July 25th. BidaskClub downgraded Mylan from a “buy” rating to a “hold” rating in a research note on Friday, June 22nd. Leerink Swann decreased their price objective on Mylan from $53.00 to $47.00 and set an “outperform” rating on the stock in a research note on Thursday, August 9th. Finally, Cantor Fitzgerald set a $41.00 price objective on Mylan and gave the stock a “hold” rating in a research note on Friday, June 29th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $47.37.

Shares of NASDAQ:MYL opened at $37.71 on Tuesday. The stock has a market capitalization of $19.72 billion, a price-to-earnings ratio of 8.30, a PEG ratio of 1.21 and a beta of 1.44. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.77 and a current ratio of 1.29. Mylan has a 52-week low of $30.69 and a 52-week high of $47.82.

Mylan (NASDAQ:MYL) last announced its earnings results on Wednesday, August 8th. The company reported $1.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by ($0.15). The firm had revenue of $2.81 billion during the quarter, compared to analysts’ expectations of $2.95 billion. Mylan had a return on equity of 18.48% and a net margin of 3.90%. The company’s revenue for the quarter was down 5.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.10 earnings per share. equities analysts anticipate that Mylan will post 4.68 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of MYL. Analyst IMS Investment Management Services Ltd. bought a new stake in Mylan during the 1st quarter valued at approximately $117,000. First Mercantile Trust Co. bought a new stake in Mylan in the 2nd quarter worth approximately $121,000. CENTRAL TRUST Co increased its stake in Mylan by 1,057.8% in the 2nd quarter. CENTRAL TRUST Co now owns 5,210 shares of the company’s stock worth $188,000 after acquiring an additional 4,760 shares during the last quarter. FTB Advisors Inc. bought a new stake in Mylan in the 2nd quarter worth approximately $188,000. Finally, Piedmont Investment Advisors LLC bought a new stake in Mylan in the 2nd quarter worth approximately $218,000. 82.31% of the stock is currently owned by institutional investors.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Read More: How to Invest in Growth Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.